← Back to home

HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)

Clinical trials for HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) explained in plain language.

Never miss a new study

Get alerted when new HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) trials appear

Sign up with your email to follow new studies for HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Last-Hope drug offered to transplant patients with deadly blood clotting disorder

Disease control APPROVED_FOR_MARKETING

This program provides access to the investigational drug narsoplimab for patients who develop a serious blood vessel complication called HSCT-TMA after a stem cell transplant. It's for adults and children who have undergone transplant and developed this life-threatening condition…

Matched conditions: HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)

Sponsor: Omeros Corporation • Aim: Disease control

Last updated Mar 27, 2026 12:39 UTC

HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)

Get alerted when new HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) trials appear

Last-Hope drug offered to transplant patients with deadly blood clotting disorder